Ocular: 'Buy' As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing

2026-02-17 13:37:15 ET

The last time I spoke about Ocular Therapeutix ( OCUL ) was regarding a Seeking Alpha article entitled " Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement ." I noted that the company was in the process of advancing its drug in several ocular disorders. One in particular was the development of AXPAXLI [OTX-TKI] for the treatment of patients with wet age-related macular degeneration [Wet-AMD]. The company was in the process of evaluating the use of this axitinib hydrogel implant in the phase 3 SOL-1 Superiority trial. I will be going over more about this study below, but the point is that the company proved that its therapy achieved superiority over a low dose [2 mg] of EYLEA [aflibercept]. The importance of this is that this is the first therapy of its kind to achieve such superiority in the targeting of patients with Wet-AMD....

Read the full article on Seeking Alpha

For further details see: